Akums Drugs and Pharmaceuticals Ltd. (AKUMS) fundamentals
Akums Drugs and Pharmaceuticals Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as AKUMS (ISIN INE09XN01023). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Akums Drugs and Pharmaceuticals Ltd. does
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. The Company offers a comprehensive range of pharmaceutical products and services in India and overseas. The Company’s segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API), Domestic Branded Formulations, International Branded Formulations, and Trade Generics. The CDMO segment is engaged in formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. The API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. The Domestic Branded Formulations segment includes marketing of its branded formulations in the Indian market. The International Branded Formulations segment undertakes the marketing of its branded formulations in the global market.
Valuation and market data
| Last close | ₹685.00 |
|---|---|
| Market capitalisation | ₹10,536 crore |
| Enterprise value | ₹11,171 crore |
| P/E (TTM) | 41.09 |
| Price to book | 3.16 |
| Price to sales (TTM) | 1.35 |
| Book value per share | ₹216.58 |
| Dividend yield | 43.80% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Tue Aug 06 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹4,488 crore | ₹382 crore | ₹256 crore | 16.67 |
| Mar 2025 | ₹4,170 crore | ₹345 crore | ₹344 crore | 22.60 |
| Mar 2024 | ₹4,212 crore | ₹-45 crore | ₹1 crore | -0.28 |
| Mar 2023 | ₹3,745 crore | ₹150 crore | ₹98 crore | 6.63 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 75.3% |
|---|---|
| Foreign institutions (FII) | 4.5% |
| Mutual funds | 7.6% |
| Other domestic institutions | 3.5% |
| Retail and others | 9.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.